COPD-ST2OP trial: Astegolimab improves health status, not exacerbations in COPD

Astegolimab improved health status but did not significantly reduce exacerbation rates over 48 weeks of treatment compared with placebo in patients with moderate to very severe COPD, according to results from the COPD-ST2OP trial.
“Interleukin-33 signaling through interleukin-1 receptor-like 1 (ST2) has been shown to drive multiple types of inflammatory responses,” Ahmed J. Yousuf, PhD, from the department of respiratory science at the Institute for Lung Health of the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, U.K., and colleagues wrote in

Astegolimab improved health status but did not significantly reduce exacerbation rates over 48 weeks of treatment compared with placebo in patients with moderate to very severe COPD, according to results from the COPD-ST2OP trial.
“Interleukin-33 signaling through interleukin-1 receptor-like 1 (ST2) has been shown to drive multiple types of inflammatory responses,” Ahmed J. Yousuf, PhD, from the department of respiratory science at the Institute for Lung Health of the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, U.K., and colleagues wrote in